Announcement: Opioid agonist treatment cuts mortality risk in French primary care—largest nationwide study yet

ბოლო განახლება: 29/08/2026 03:30

ავტორი:

0 Min Read

A nationwide French cohort study published in The Lancet Public Health demonstrates that opioid agonist treatment substantially reduces mortality risk among people with opioid use disorder in primary care, with buprenorphine showing particularly marked benefits. The findings validate primary care decentralisation of OAT delivery. — Photo by MART PRODUCTION on Pexels (Pexels License)

1 min read|52 words

New nationwide French evidence: opioid agonist treatment (OAT) is associated with a large decrease in all-cause mortality, especially buprenorphine. The study validates primary care as an effective setting for OAT delivery, expanding access beyond specialised clinics. Read the full analysis from The Lancet Public Health.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Opioid agonist treatment cuts mortality risk in French primary care—largest nationwide study yet →

Share This Article

ავტორი:Prof. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: Opioid agonist treatment cuts mortality risk in French primary care—largest nationwide study yet

Submit Your Paper →

Georgian Dictionary of Public Health

Balance Problems and the Vulnerable Mind: A Gene Study Links the Inner Ear to Cognition

Screening Young Athletes’ Hearts: What a Georgian Cohort Reveals

Submit Your Paper to GMJ

Company

You Might Also Like